【国民娱乐每日礼金gm777.top,福建快3今天开奖结果中大奖】我们为您提供福建快3今天开奖结果注册,福建快3今天开奖结果投注,福建快3今天开奖结果app,福建快3今天开奖结果平台,巨华彩票开户,充提快速,操控简单,为福建快3今天开奖结果彩民服务!

當前位置:首頁  科技動態  學術報告

10月17日 黃力夫教授講座信息

時間:2019-10-11瀏覽:10

中醫藥交叉科學前沿論壇

報告題目Ratiometric Co-loading and Co-delivery of Drugs in Nanoparticles for Cancer Therapy

時間:20191017日(周四)9:30

地點:全球合作伙伴中心報告廳

報告人:黃力夫 教授




黃力夫教授Leaf Huang, Ph.D. is the Fred Eshelman Distinguished Professor, Division of Pharmacoengineering and Molecular Pharmaceutics in the Eshelman School of Pharmacy, University of North Carolina at Chapel Hill. Dr. Huang’s research has been in the area of gene therapy and targeted drug delivery. He has pioneered the liposome non-viral vector and has designed and manufactured the cationic lipid vector for the first non-viral clinical trial in 1992. His current work centers on nanoparticle vectors for gene transfer in tumor and liver. He also continues research in establishing a ligand targeted delivery system for cDNA, mRNA, siRNA, proteins and peptides for tumor growth inhibition and for vaccines in treating cancer and infected diseases.  He has authored or co-authored more than 600 papers with an H-index of 121. He is also the inventor or co-inventor of 22 US and foreign patents. In 2004, he received the Alec D. Bangham MD FRS Achievement Award, which is the highest honor in liposome research. He was the recipient of the 2013 Distinguished Pharmaceutical Scientist Award which is the highest scientific recognition of the American Association of Pharmaceutical Scientists. He was named a Highly Cited Researcher in “Pharmacology & Toxicology” since 2016. Dr. Huang has also co-founded 6 biotech start-ups in the past.


報告摘要Combination therapy is a routine practice in cancer therapy. Due to difference in PK and biodistribution of drugs, precise prediction of optimal dose and dosing schedule has been challenging. Prof. Huang will describe the theory and the practice of ratiometric co-loading and co-delivery of two or more drugs in nanoparticles for optimal efficacy and minimal toxicity. Emphasis will be drug combinations to induce immunogenic cell death for immunotherapy of cancer.


返回原圖
/

福建快3今天开奖结果